Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

6.87USD
23 May 2017
Change (% chg)

-- (--)
Prev Close
$6.87
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
393,200
52-wk High
$11.71
52-wk Low
$4.01

PGNX.OQ

Chart for PGNX.OQ

About

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging... (more)

Overall

Beta: 3.38
Market Cap(Mil.): $482.45
Shares Outstanding(Mil.): 70.23
Dividend: --
Yield (%): --

Financials

  PGNX.OQ Industry Sector
P/E (TTM): 66.33 139.31 17.29
EPS (TTM): 0.10 -- --
ROI: 5.07 2.29 -5.84
ROE: 8.48 0.06 -5.23

BRIEF-Progenics Pharmaceuticals reports Q1 loss per share $0.23

* Progenics pharmaceuticals announces first quarter 2017 financial results and business update

May 04 2017

BRIEF-Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®

* Progenics Pharmaceuticals announces positive topline results from registrational phase 2b trial of azedra®

Mar 30 2017

BRIEF-Progenics Pharmaceuticals posts Q4 loss per share $0.10

* Progenics Pharmaceuticals announces fourth quarter and full-year 2016 financial results and business update

Mar 09 2017

BRIEF-Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment

* Progenics Pharmaceuticals announces initiation of a phase 1 clinical trial of its PSMA-targeted therapeutic candidate 1095 for the treatment of metastatic prostate cancer Source text for Eikon: Further company coverage:

Feb 14 2017

BRIEF-Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald

* Entered controlled equity offering sales agreement with Cantor Fitzgerald, pursuant to which Co may offer, sell up to $75 million stock Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Progenics Pharmaceuticals files for mixed shelf of up to $250 mln - SEC filing

* Progenics Pharmaceuticals Inc - files for mixed shelf of up to $250 million - SEC filing Source text: (http://bit.ly/2jcUEzy) Further company coverage:

Jan 06 2017

More From Around the Web

Earnings vs. Estimates